Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Lisata Therapeutics (0HS8) Share Price & Analysis

0 Followers

0HS8 Stock Chart & Stats

$1.18$0.15(14.01%)
At close: 4:30 PM GMT
$1$1.5$2Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.02 - $1.42
52-Week Range
$0.98 - $5.10
Previous Close
$1.04
Volume
N/A
Average Volume (3M)
2,456
Market Cap
$11.02M
Enterprise Value
$20.26M
Total Cash (Recent Filing)
$10.44M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.26
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

Zero debt reduces interest and refinancing pressure, giving the company greater financial flexibility while it advances clinical programs. This conservative leverage profile can help preserve strategic options and lower solvency risk over the next several quarters, despite ongoing losses.

Multi-Year Funding

The substantial financing extends the operating runway and supports development of MAR001/005 and MAR002 through Phase 2 milestones. Multi-year funding improves the company’s ability to execute clinical plans without immediately relying on additional capital.

Leadership And Strategic Expertise

Adding an independent director with extensive biopharma finance and public-company experience strengthens oversight during a major strategic transition. Greater board expertise may improve capital allocation, governance, and execution as the company advances its clinical portfolio.

Bears Say

Minimal And Declining Revenue

Very low and declining revenue indicates limited commercial traction and leaves the company highly dependent on clinical development success rather than established operating income. This weak revenue base makes it difficult to absorb expenses or move toward sustainable profitability.

Persistent Cash Burn And Losses

Large recurring losses and negative operating and free cash flow show that the business is not self-funding. Continued cash consumption will require disciplined execution and may create ongoing dependence on external financing as clinical programs progress.

Severe Shareholder Dilution

The transaction materially reduced legacy holders’ ownership and introduced preferred securities with potential conversion into common stock. This dilution can limit existing shareholders’ economic participation and makes future value creation more dependent on successful clinical execution.

Lisata Therapeutics News

0HS8 FAQ

What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest share price was $0.98 and its highest was $5.10 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $11.02M.
When is Lisata Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Aug 17, 2026. The company reported -$0.322 earnings per share for the quarter.
Is Lisata Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics does not currently pay dividends.
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 10,804,066 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.322 in its last earnings report. Following the earnings report the stock price went down -5.075%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in GB:0HS8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology